Drug Industry Anticipates More Work Ahead Following Health Care Reform Bill’s Final Passage

While praising individual provisions of the final health care overhaul bill, pharmaceutical industry groups said that the legislation the House approved March 21 is an imperfect measure, and they will continue to work on issues such as pay-for-delay patent settlements and generic competition with biologic drugs.